Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
Clin Gastroenterol Hepatol. 2021 Mar;19(3):616-617. doi: 10.1016/j.cgh.2020.02.017. Epub 2020 Feb 14.
The global incidence of inflammatory bowel disease (IBD) has increased considerably during the past few decades. IBDs, composed of Crohn's disease (CD) and ulcerative colitis (UC), are characterized by heterogeneous presentation and widely variable clinical course. The therapeutic goals are to induce and maintain remission. Despite the current treatments available, many patients do not achieve this goal.
在过去几十年中,炎症性肠病(IBD)的全球发病率显著上升。IBD 由克罗恩病(CD)和溃疡性结肠炎(UC)组成,其特征为表现多样且临床病程差异大。治疗目标是诱导并维持缓解。尽管目前有多种治疗方法,但许多患者无法实现这一目标。